You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
AMRX reported third-quarter revenue of $863 million, up 10 percent, adjusted EBITDA of $207 million, up 30 percent, and adjusted EPS of $0.26, up 53 percent. It raised 2026 revenue guidance to $3.15 to $3.25 billion.
Amneal Pharmaceuticals reported third-quarter 2026 net revenue of $863 million and adjusted EBITDA of $207 million, while raising 2026 net revenue guidance to $3.15 billion - $3.25 billion and adjusted EBITDA guidance to $800 million - $815 million.
Amneal Pharmaceuticals added Kashiv BioSciences, LLC financial statements and pro forma information; Kashiv had a $109,051,391 net loss and substantial doubt about continuing as a going concern.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 revenue, adjusted EBITDA, and adjusted diluted EPS grew 10%, 30%, and 53%, respectively, while management raised full-year guidance and expects 2030 revenue of about $4.3 billion to $4.5 billion. The principal offsets were a $22 million GAAP net loss, a 17% AvKARE revenue decline, lower operating cash flow guidance, acquisition and legal charges, and net leverage of 3.9x versus 3.5x at year-end 2025.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share (Non-GAAP) non-GAAP | $0.57 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA (Non-GAAP) non-GAAP | $408.46M | Six Months Ended June 30, 2026 | — |
| Adjusted net income (Non-GAAP) non-GAAP | $188.38M | Six Months Ended June 30, 2026 | — |
| EBITDA (Non-GAAP) non-GAAP | $350.56M | Six Months Ended June 30, 2026 | — |
| Gross margin % non-GAAP | 46.2% | Three Months Ended June 30, 2026 | — |
| Net debt (Non-GAAP) non-GAAP | $2.66B | June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRX
this stock
Amneal Pharmaceuticals, Inc.
|
$7.45B | +69.7% | +8.0% | 52.2 | 3.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRX | +6.2% | +11.5% | +67.2% | -0.6% | +69.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.6% | +12.6% | +66.7% | -0.4% | +59.1% |
